chrisvoncsefalvay/vaers-outcomes huggingface dataset:
On examination, she has as weakness, on her left arm, she is at least a 2 over 5 on her deltoids, biceps, she is able to move her hands, she is not having any numbness on her left hands. She is not having any neck pain. This started 5 hours after her pneumococcal vaccination, at this time I will treat her for possible brachial  neuritis related from her vaccination, she will need to be closely followed up, I would recommend she start prednisone 20 milligram 2 tablets daily, for 7 days.  Side effects such as gastritis, insomnia were discussed. Differential diagnosis to be considered includes cervical radiculopathy, adhesive capsulitis, rotator cuff tear, although patient stated this came on suddenly and she
numbness and tingling down the side of my neck; numbness and tingling down the side of my neck; This spontaneous case was reported by a consumer and describes the occurrence of HYPOAESTHESIA (numbness and tingling down the side of my neck) and PARAESTHESIA (numbness and tingling down the side of my neck) in a 57-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047A21A) for COVID-19 vaccination.     The patient's past medical history included Root canal procedure (one month prior to first vaccine dose) in February 2021.    On 19-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Mar-2021, the patient experienced HYPOAESTHESIA (numbness and tingling down the side of my neck) and PARAESTHESIA (numbness and tingling down the side of my neck). At the time of the report, HYPOAESTHESIA (numbness and tingling down the side of my neck) and PARAESTHESIA (numbness and tingling down the side of my neck) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Reporter did not allow further contact
Extremity due to vaccine; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team.  A 16-year-old patient received bnt162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: LIMB DISCOMFORT (non-serious), outcome "unknown", described as "Extremity due to vaccine".
Waited 15 min. after shot in office, felt fine so went home. Started feeling itching B/L hips and spread down thighs. Saw hives. Took BENADRYL x1 dose, most of it went away. No sob/swelling. No other new exposures.
It was reported that a pt (4 of 9) received a Tripedia vaccination the week of 3/23/01. Reportedly, sometime after the vaccination (date not specified), the pt developed a large local reaction at the injection site. From additional correspondence received on 5/16/01, additional pt, vaccine administrator and responsible physician information was provided.
Swelling, erythema and Ecchymosis of 2cm diameter at injection site. Also, c/o ear pain and URI, thought to be coincidental.
Swelling and pain at and around injection site which then a small bump under the skin formed about 6 inches below injection site. She says the large amount of swelling did dissipate. However she claims of pain that extends from elbow to hand at times and pain near injection site when palpated enough to disturb her even during work which she works at a computer. Patient says on 09/26/2017 at doctor's visit the doctor recommended hot compress and acetaminophen. Patient used hot compress and found some relief but did not see value in acetaminophen but still has pain.
This case was reported by a physician and described the occurrence of fever in a 36-year-old female subject who was vaccinated with HAVRIX (GlaxoSmithKline). On 9 June 2013 the subject received a dose of HAVRIX (1 ml, unknown route, left arm). In June 2013, less than one week after vaccination with HAVRIX, the subject presented to the physician having experienced fever, joint pain, joint swelling, rash, flu like symptoms and walking difficulty. At the time of reporting the events were unresolved. The physician reported another case with HAVRIX. See case A1031798A for details on the other case.
Patient called PA and told her he woke up at 0900 and he had lip swelling, a rash all over his trunk, some throat congestion, and pressure to his chest. Patient had taken some Benadryl prior to calling into our clinic. PA advised patient to go to ER to be seen.  Patient was seen and treated in the Emergency Dept at Hospital at 1057 and given IV Methylprednisone 125mg, Diphenhydramine 25mg PO, and femotidine 20 mg IV. 11:10AM pt c/o fatigue, post vaccine O: BP 220/110 P 90 regular RR 12 O2 100% no allergies no significant PMH 11:20AM BP 190/92 EMT - called ER MD pt instructed to go to urgent care or ER with family. 11:30AM signed AMA and left clinic
Fever of 100, nausea,  injection site pain, lympnoid pain right side into right breast, stiff neck, all over pain ,achness, headache, fatigue and all over chills. Took tylonal and went to bed for 14 hours. Still experiencing pain, slight headache and achness all over. Fever and nausea gone.
R deltoid with large localized erythematous lesion consistent with allergic reaction.Fever of 102 on 7/16/08 and Temp 101 0n 7/17/08.Treated with benadryl, ice  and ibuprofen. Medrol dose pack was prescribed prn.
Within 3 minutes of influenza vaccine administration, patient reported feeling dizzy, warm, and light headed. Client was already seated in a reclined position on the exam table, as they reported happening with prior vaccine administrations (although not consistently). Client's color turned pale. Vital signs were taken. Pulse palpated and it was +2, regular rate. Pt reported feeling worse, so I had patient lie back flat with knees bent and feet resting on the exam table. Client reported "Wow, that really helped. I feel better already." Client observed for an additional 20 minutes. After 5 minutes from onset of symptoms, patient had returned to baseline. Last BP was 109/71 (89). Client given apple juice and graham crackers prior to vaccine administration and water afterwards. Follow up phone call made and client reported complete resolution of symptoms.
pain; Received at shoulder joint capsule; This case was reported by a other health professional via call center representative and described the occurrence of injection site pain in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced injection site pain and vaccine administered at inappropriate site. On an unknown date, the outcome of the injection site pain and vaccine administered at inappropriate site were unknown.   It was unknown if the reporter considered the injection site pain to be related to Shingrix.     Additional Information: GSK Receipt Date: 19-OCT-2022 Reporter's Comment: Reporter stated that patient received her first Shingrix vaccine inadvertently in her shoulder joint capsule. Patient went to orthopedist due to pain and they confirmed Shingrix was improperly administered in the shoulder joint capsule. The patient was now due for her 6 month booster. Should this be considered the initial dose or second and final dose. HCP disconnected the chat after asked for patient demographics, therefore no additional information available. Follow up permission was not obtained due to this and unknown if address on file was correct. No additional details provided by HCP (ie, location of the injection (which arm), resolution, etc) as HCP was in a hurry to return back to awaiting patients in office. Additional supportive information: As patient received improper administration of vaccine which led to vaccine administered at inappropriate site. The case US2022150638 was identified as duplicate of US2022150639. The case US2022150639 would be voided, and all the future correspondence would be added in this case US2022150638 which stands as a case of record for this patient.
Patient (pt) is a 41 year old who received his first and only anthrax immunization on 15 Mar 04. He stated that within 30-40 minutes after the immunization he started to develop a headache, which he noticed between his temples. He stated that he never had pain like this before and described the pain as constant and rated it a number 5-6 on pain scale of 1-10 with 10 being worse. He said he developed the pain while driving with his wife on their way for a mini vacation. He said he became uncomfortable and pulled over so wife can drive while he rested.  Approximately 3 ½ hours later, when he woke up he noticed that he had problems focusing and that his vision was blurred. He reported no relief from Tylenol and that the pain remained a # 4-5. He denied nausea, vomiting, altered sensation and reported that his close vision remained blurred until one day after his headaches ceased. He stated it was difficult to focus on road signs. He stated that the headache lasted a total of 3 days before it subsided on day 4 and his vision returned to normal on day 5. Pt also reported that on the day after his shot he went on a little hike, on the beach and through a wooded area, with his wife and when he returned he noticed a rash on his upper legs, abdomen and chest. He was wearing shorts and a shirt. Rash described as red raised bumps without pus or fluid and with slight itching. The rash lasted 5-6 days and he did not apply any creams or lotions. He denied anything unusual in his routine and that there has been no reoccurrence. He stated that his wife did not develop any skin lesions.   He reported that he did not seek any medical attention. He also noted that even though he went on a little hike that they normally do an extensive hike, which, he was unable to do on this trip because of his headaches and vision changes.  The patient reports no further episodes of headaches, vision changes or skin rash since that first episode following his anthrax vaccination.
30min p/vax pt c/o h/a, dizziness cont until 10/21/99 when h/a, dizziness then fell down;saw MD x 2;this week no localized rxn;fever 94.7-101.4;cont to collapse suddenly from dizziness;
Patient received Covid Vaccine Dose 1 on 01/25/2021. Patient states within 15-20 mins of receiving dose, felt extreme coldness from shoulder to tips of fingers for about 30 mins and then resolved.  Then afterwards, started to develop redness/itching/hives on back.   Patient also felt very lightheaded and blood pressure taken and elevated at 188/84. (20-25 mins after injection).  Injection site did swell and got red after.  Also had mild HA after arriving home but didn't last long & nauseous feeling the whole day after getting vaccine.    Patient did not take any medications and all symptoms resolved on own.
took the shot , it gave her shingles/suspected vaccination failure; shingles; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a female patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.  Additional details reported as follows: The case was reported by the patient's grandparent. The age at vaccination was not reported. The patient took the Shingles shot and it gave her the shingles. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset and laboratory confirmation of shingles were unknown at the time of reporting.
Right after vaccination I had sharp  chest pain, also in my left arm, headache, nausea, dizziness, vertigo. Was brought  an ice pack and water. Symptoms lasted for 30 minutes after injection, tapering off. headaches and muscle aches continued for a week. Dizziness and headaches continue. Saw doctors in December. Checked inner ear and vestibular system. Being treated with physical exercises. No menstrual cycle since October, not pregnant.
Symptoms started slowly, milder in character. On 11/17/2009 symptoms were increasing in character and severity with mild headache, muscle ache, sore throat, and congestion. From 11/18/2009 through 11/19/2009, symptoms were severe including high fever (105 degrees F), severe muscle aches, moderate to severe fluctuating headache, stomach ache, sore throat, congestion, and loss of appetite. On the evening of 11/18/2009 my husband described that I had an episode of disorientation, abnormal behavior, and high fever lasting from just before midnight to approximately 03:00 AM on 11/19/2009. Severe symptoms continued on 11/19/2009 with slight improvement as the day progressed. Symptoms improved on 11/20/2009 and included sore throat, loss of appetite, chills, and stomach ache.
on 7th day post vaccination, I had left upper arm swelling, rash, and pain where there had previously been none. Freckles on that upper arm scabbed over and peeled. This event lasted less than 2 hours. No medications taken, no medical care received. No further reaction since then.
This is a spontaneous case, initially received from other non-health professional on 01-Nov-2018, concerning a 45-year-old, adult female patient. The patient's current condition included hyperthyroidism and concomitant medication included LEVOTHROID for an unknown indication. On an unspecified date, following the power outage the temperature at which the vaccine stored reached a maximum temperature of 10.1 C for 90 minutes. This was first time excursion. On 01-Nov-2018, the patient was administered FLUCELVAX QIVc (dose: 0.5 ml, route of administration: intramuscular, anatomical location: deltoid, batch number: 252676 and expiry date: 30-Jun-2019) which underwent temperature excursion. At the time of this report, no adverse event was reported. The reporter assessed this case as non-serious.
In April, 1999, the pt received her 1st dose of Lymerix with no untoward effects. In May, 1999, she received her 2nd dose and on 6/19/99, after working outdoors the previous day, she experienced a rash between her big toe and 2nd toe "and a small bite on her hip". Over the next 2 days, she "experienced chills and uncontrollable shaking". She was treated with doxycyoline and Lyme disease test were performed. According to the note of her infectious disease specialist, she was hospitalized on 6/23/99 for this reason. The pt also had a fever, bull's eye lesions, and somewhat elevated liver function tests. The physician concluded "she had a component of human granulocyte ehrlichiosis plus possible Lyme disease manifested with her tick born febrile illness". She was treated with Rocephin, amoxicillin, Vioxx, levofloxacin, Celebrex and oral doxycycline and she had marked improvement of her symptoms to near baseline. The leukopenia and thrombocytompenia appeared to have resolved after treatment and completion of betalactam antiobiotic. However, in 11/99, the pt reported to her physician she had "increasing discomfort in her joints". At this time a Western blot for Lyme IgG antibody had 1 band at 41 kilodaltons, but the entire Lyme IgG Western blot interpretation was negative for anti Lyme IgG erythrocyte sed rate was 22mm/hr (normal). Follow-up notes 4 weeks later, reveals the pt claims to be "still very tired, aches all over, and it hurts to walk. It was alleged, at this point the physician considered "chronic Lyme arthritis" as a possible dx. The most recent information received on 6/26/00, reported on 1/11/00, the pt started Celebrex for empiric treatment of arthralgias and myalgias and had some relief of symptoms. She developed a very pruritic rash on her neck, buttocks, somewhat on her trunk and back of her legs. The physician believed the rash to be an underlying psoriasis, but he felt the lesions are most typical of a folliculitis, perhaps a pityorsporum folliculitis which could be related to her ungoing use of antibiotics.
considerably sore arm - left arm; pain in arm; a red rash - left arm; swelling at the injection site - left arm; itchy - at the injection site - left arm; I started to feel very sick; felt like I've been hit by a truck; diarrhea; lightheaded for several hours; achy body - aches all over; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 29-Mar-2021 and was forwarded to Moderna on 29-Mar-2021.    This spontaneous case was reported by a consumer and describes the occurrence of MALAISE (I started to feel very sick), FEELING ABNORMAL (felt like I've been hit by a truck), DIARRHOEA (diarrhea), HEADACHE (lightheaded for several hours) and MYALGIA (achy body - aches all over) in a 54-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 021821A and 010A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 26-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Mar-2021, the patient experienced MALAISE (I started to feel very sick), FEELING ABNORMAL (felt like I've been hit by a truck), DIARRHOEA (diarrhea), HEADACHE (lightheaded for several hours) and MYALGIA (achy body - aches all over). On an unknown date, the patient experienced VACCINATION SITE PAIN (considerably sore arm - left arm), VACCINATION SITE PAIN (pain in arm), RASH (a red rash - left arm), VACCINATION SITE SWELLING (swelling at the injection site - left arm) and VACCINATION SITE PRURITUS (itchy - at the injection site - left arm). The patient was treated with PARACETAMOL (TYLENOL) on 27-Mar-2021 for Adverse event, at an unspecified dose and frequency. On 27-Mar-2021, MALAISE (I started to feel very sick), FEELING ABNORMAL (felt like I've been hit by a truck), DIARRHOEA (diarrhea), HEADACHE (lightheaded for several hours) and MYALGIA (achy body - aches all over) had resolved. At the time of the report, VACCINATION SITE PAIN (considerably sore arm - left arm), VACCINATION SITE PAIN (pain in arm), RASH (a red rash - left arm), VACCINATION SITE SWELLING (swelling at the injection site - left arm) and VACCINATION SITE PRURITUS (itchy - at the injection site - left arm) outcome was unknown.            No concomitant medications were provided.
PATIENT BEGAN HAVING FLUSHING IMMEDIATELY AFTER RECEIVING ADDITIONALLY SHE BEGAN TO HAVE A PERSISTENT COUGH APPROX. 5 MIN. POST INJECTION.
diagnosed with covid after first dose of the vaccine; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 29-Sep-2021 and was forwarded to Moderna on 29-Sep-2021.    This spontaneous case was reported by a nurse and describes the occurrence of COVID-19 (diagnosed with covid after first dose of the vaccine) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 040C21A) for COVID-19 vaccination.     No medical history was provided.     On 27-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced COVID-19 (diagnosed with covid after first dose of the vaccine). At the time of the report, COVID-19 (diagnosed with covid after first dose of the vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medications was not provided by the reporter Treatment information was not provided; Sender's Comments: This case concerns a 40-year-old female with a non-serious unexpected event of COVID-19. Event onset with unknown latency after first dose mRNA-1273. Event outcome unknown. No information reported on second dose and rechallenge. Reporter causality not provided. Causality possible based on temporal association. Events consistent with known profile of mRNA-1273. The benefit-risk relationship of mRNA-1273 is not affected by this report.
This case was reported by a physician via call center representative and described the occurrence of slurred speech in a female patient who received SHINGRIX (batch number LT533, expiry date 11th October 2020) for prophylaxis. On 23rd June 2018 12:13, the patient received the 1st dose of SHINGRIX (intramuscular). On an unknown date, less than a week after receiving SHINGRIX, the patient experienced slurred speech, weakness, abdominal crampy pains, rigors, low back pain, dizziness, word finding difficulty and nausea. The patient was treated with BENADRYL, REGLAN and BENTYL. On an unknown date, the outcome of the slurred speech, weakness, rigors, low back pain, dizziness and word finding difficulty were recovered/resolved and the outcome of the abdominal crampy pains and nausea were not recovered/not resolved. The reporter considered the slurred speech, weakness, abdominal crampy pains, rigors, low back pain, dizziness, word finding difficulty and nausea to be related to SHINGRIX. Additional details were provided as follows: The patient received SHINGRIX vaccine on unknown deltoid. The health care professional reported patient developed stroke like symptoms such and slurred speech and not being able to put words together after receiving the first SHINGRIX dose. The patient also experienced severe weakness, rigors, nausea, abdominal pain/cramping, severe low back pain and severe dizziness. The health care professional stated that patient was not herself. The health care professional said slurred speech went away after the patient took 2 BENADRYL. The patient was still experiencing nausea and abdominal cramping in the mornings and was taking REGLAN and BENTYL now. The health care professional felt that these effects were caused by the SHINGRIX. The health care professional did not feel that patient was jeopardized at the time of reporting but felt that the patient would be if they received the second dose of the series. The health care professional would not give the patient the second dose of the series.
fever up to 102.4 day following vaccine for approx. 28 hours, joint pain, severe headache with the fever. On the 30th 3 days after vaccine 4 large fever blisters appeared. On the 31st sores inside mouth and on tongue, feels like I burned my mouth. On 2/1 my lips started peeling as if they had been burned. Today my lips are still peeling and the fever blisters have started to crust over.